The global market for Endoscopic Retrograde Cholangiopancreatography was valued at US$2.1 Billion in 2025 and is projected to reach US$3.8 Billion by 2032, growing at a CAGR of 8.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.
The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.
Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.
Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market - Key Trends & Drivers Summarized
Why Is ERCP a Critical Procedure in Gastrointestinal and Hepatobiliary Medicine?
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive endoscopic technique used for the diagnosis and treatment of biliary and pancreatic disorders, including gallstones, bile duct strictures, pancreatic tumors, and chronic pancreatitis. This procedure combines endoscopy and fluoroscopy to visualize and treat conditions affecting the biliary and pancreatic ducts, reducing the need for open surgical interventions.The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.
What Are the Latest Innovations in ERCP Technology?
Recent advancements in ERCP have focused on enhancing visualization, reducing complications, and improving therapeutic precision. The development of high-definition digital fluoroscopy and AI-assisted cholangiography interpretation has improved the detection of small lesions and bile duct abnormalities. SpyGlass Direct Visualization Systems, a state-of-the-art cholangioscopy platform, allows real-time imaging of bile and pancreatic ducts, enabling targeted biopsy collection and precision-guided stone removal.The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.
What Is Driving the Growth of the ERCP Market?
The growth in the ERCP market is driven by rising gastrointestinal disorders, increased adoption of minimally invasive techniques, and advancements in endoscopic imaging and intervention tools. The growing preference for non-surgical treatments for biliary and pancreatic diseases, combined with the expansion of advanced endoscopy centers, has fueled market demand. Additionally, the rise in pancreatic cancer incidence and the increasing need for therapeutic endoscopic procedures have contributed to ERCP adoption.Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.
Report Scope
The report analyzes the Endoscopic Retrograde Cholangiopancreatography market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others); Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation); End-Use (Hospitals, Outpatient Facilities).
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Endoscopes segment, which is expected to reach US$1.5 Billion by 2032 with a CAGR of a 10.3%. The Endotherapy Devices segment is also set to grow at 8.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $615.8 Million in 2025, and China, forecasted to grow at an impressive 8.3% CAGR to reach $665.3 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Endoscopic Retrograde Cholangiopancreatography Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Endoscopic Retrograde Cholangiopancreatography Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Endoscopic Retrograde Cholangiopancreatography Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Ambu A/S, Ambu Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Bio-Rad Medisys Pvt. Ltd. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Endoscopic Retrograde Cholangiopancreatography market report include:
- Ambu A/S
- Ambu Inc.
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- Bio-Rad Medisys Pvt. Ltd.
- Boston Scientific Corporation
- CONMED Corporation
- Cook Medical
- DCC Healthcare (Medi-Globe GmbH)
- Fujifilm Holdings Corporation
- HOBBS MEDICAL
- HOYA Corporation
- Huger Medical Instrument Co., Ltd
- Johnson & Johnson
- KARL STORZ SE & Co. KG
- Lancetinc Medical
- LeoMed
- Medtronic PLC
- Merit Medical Systems
- Olympus Corporation
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ambu A/S
- Ambu Inc.
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- Bio-Rad Medisys Pvt. Ltd.
- Boston Scientific Corporation
- CONMED Corporation
- Cook Medical
- DCC Healthcare (Medi-Globe GmbH)
- Fujifilm Holdings Corporation
- HOBBS MEDICAL
- HOYA Corporation
- Huger Medical Instrument Co., Ltd
- Johnson & Johnson
- KARL STORZ SE & Co. KG
- Lancetinc Medical
- LeoMed
- Medtronic PLC
- Merit Medical Systems
- Olympus Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 183 |
| Published | November 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 2.1 Billion |
| Forecasted Market Value ( USD | $ 3.8 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
